Technology
Health
Biotechnology

Ligand Pharmaceuticals

$123.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-0.26%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell LGND and other stocks, options, ETFs, and crypto commission-free!

About

Ligand Pharmaceuticals Incorporated Common Stock, also called Ligand Pharmaceuticals, is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Read More The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Employees
116
Headquarters
San Diego, California
Founded
1987
Market Cap
2.58B
Price-Earnings Ratio
22.09
Dividend Yield
0.00
Average Volume
531.34K
High Today
$125.88
Low Today
$121.98
Open Price
$124.02
Volume
191.26K
52 Week High
$278.62
52 Week Low
$98.56

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

News

Guru FocusMar 15

Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares

CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 03/13/2019 at an average price of $114.29 a share.

214
Yahoo FinanceMar 15

LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

American International Group (AIG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive gr...

160
Simply Wall StMar 13

Should You Be Excited About Ligand Pharmaceuticals Incorporated’s (NASDAQ:LGND) 26% Return On Equity?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. To keep the lesson grounded in practicality, we’ll use ROE to better understand Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Over the last twelve months Ligand Pharmaceuticals has recorded a ROE of 26%. One way to conceptualize this, is that for each $1 of shareholders’ equity it has, the company made $0...

139

Earnings

$0.46
$1.17
$1.88
$2.59
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.